As per the terms of the agreement, Elite will conduct the laboratory stability studies, manufacturing and packaging for two generic products: Isradipine capsules USP, 2.5mg and 5mg and Phendimetrazine Tartrate tablets USP, 35mg.
Elite will be compensated at an agreed upon transfer price for the manufacturing and packaging of the products.
Elite is eligible to receive a 10% royalty on net profits for Isradipine finished products from Mikah and will also receive a onetime milestone payment for each product for the work associated with the technology transfer.